SHAREHOLDERS’ AGREEMENTShareholders Agreement • March 21st, 2022 • Balanced Pharma Inc • North Carolina
This Shareholders’ Agreement (this “Agreement”) is made and entered into as of December ___, 2020, by and among Balanced Pharma Incorporated, a Delaware corporation (the “Company”), the parties listed on Exhibit A attached hereto (the “Investors”) and the parties listed on Exhibit B attached hereto (the “Key Holders” and collectively, with the Investors, the “Shareholders”).
SUBSCRIPTION AGREEMENTSubscription Agreement • March 21st, 2022 • Balanced Pharma Inc • Delaware
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET IS EXPECTED TO DEVELOP FOLLOWING THIS OFFERING.
Broker-Dealer AgreementBroker-Dealer Agreement • March 21st, 2022 • Balanced Pharma Inc
This agreement (together with exhibits and schedules, the “Agreement”) is entered into by and between Balanced Pharma Incorporated (“Client”), a Delaware Corporation, and Dalmore Group, LLC., a New York Limited Liability Company (“Dalmore”). Client and Dalmore agree to be bound by the terms of this Agreement, effective as of January 10, 2022 (the “Effective Date”):
ADDENDUM TO BROKER/DEALER AGREEMENTBroker/Dealer Agreement • July 19th, 2022 • Balanced Pharma Inc • Pharmaceutical preparations
This is an addendum to the broker/dealer agreement (“Addendum”) between Dalmore Group, LLC and Balanced Pharma, Inc. (“Issuer Name” or “Client”) dated April 1, 2022. This Addendum is effective as of July 13, 2022. This Addendum will update Section 3 (“Compensation”) of the original Agreement. Specifically, as compensation for the Services, Client shall pay to Dalmore a fee equal to one percent (1%) on the aggregate of amounts raised as a result of investors that initiated their investment not referred by Dalmore and an additional five percent (5%) on the aggregate amount raised as a result of investors that initiated their investment through a referral from Justly.
Broker-Dealer AgreementBroker-Dealer Agreement • July 19th, 2022 • Balanced Pharma Inc • Pharmaceutical preparations
This agreement (together with exhibits and schedules, the “Agreement”) is entered into by and between Balanced Pharma Incorporated (“Client”), a Delaware Corporation, and Dalmore Group, LLC., a New York Limited Liability Company (“Dalmore”). Client and Dalmore agree to be bound by the terms of this Agreement, effective as of April 1, 2022 (the “Effective Date”):
